Dr. King on Role of Sentinel Lymph Node Biopsy in Breast Cancer

Tari King, MD, FACS
Published: Monday, Jan 29, 2018



Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.

Sentinel lymph node biopsy remains an important procedure used in patients with breast cancer, says King, as axillary staging is still needed. There needs to be some assessment if there is cancer in the lymph node, as it can guide treatment, King explains. Steps are being taken to phase out the procedure in some patients.

In the next 10 years, King says that efforts will increase in order to identify which patients do not need to undergo a sentinel lymph node biopsy. There are currently 2 ongoing trials comparing sentinel lymph node biopsy to axillary observation in women who had a normal ultrasound.
 


Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.

Sentinel lymph node biopsy remains an important procedure used in patients with breast cancer, says King, as axillary staging is still needed. There needs to be some assessment if there is cancer in the lymph node, as it can guide treatment, King explains. Steps are being taken to phase out the procedure in some patients.

In the next 10 years, King says that efforts will increase in order to identify which patients do not need to undergo a sentinel lymph node biopsy. There are currently 2 ongoing trials comparing sentinel lymph node biopsy to axillary observation in women who had a normal ultrasound.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x